Press Releases

InVivo Therapeutics Provides Clinical Update and Reports 2017 First Quarter Financial Results

Published: May 4, 2017

– INSPIRE Patient Updates – CAMBRIDGE, Mass. (May 4, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today provided a clinical update, an update on patients in the INSPIRE study of the Neuro-Spinal Scaffold™, and reported financial results for the quarter ended March 31, 2017. Clinical/Regulatory Update Mark Perrin, InVivo’s Chief Executive Officer and Chairman, said, “In the first quarter, we continued to make significant progress at InVivo and with the INSPIRE study. By early April, we had enrolled four new patients into the INSPIRE study, with three patients enrolled within 30 days of each other. We also announced four new […]

View Article
InVivo Therapeutics Announces Oral Presentations at the 2017 American Spinal Injury Association Annual Scientific Meeting

Published: April 20, 2017

CAMBRIDGE, Mass. (Apr 20, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company will be giving two oral presentations at the 2017 American Spinal Injury Association (ASIA) Annual Scientific Meeting to be held April 26-29, 2017 in Albuquerque, New Mexico. Alex Aimetti, Ph.D., Vice President, Medical Education and Scientific Support, will present a clinical trial update during the “Clinical Trials 360-degree” session sponsored by Spinal Cord Outcomes Partnership Endeavor (SCOPE) on Friday, April 28. Dr. Aimetti will also present an abstract entitled “Relationship of ASIA Impairment Scale (AIS) Grade to Post-injury Hospitalization Costs in Thoracic Spinal Cord […]

View Article
InVivo Therapeutics Announces New Site for INSPIRE Study

Published: April 10, 2017

CAMBRIDGE, Mass. (Apr 10, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the Brigham and Women’s Hospital (BWH) in Boston, MA has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. BWH is a teaching hospital of Harvard Medical School and hosts one of the largest neurosurgical intensive care units in the country. “Patients who suffer spinal cord injury face limited options for treatment.  I’m hopeful that spinal cord research, particularly in the area […]

View Article
InVivo Therapeutics Announces New Patient Enrollment into the INSPIRE Study at the Carolinas Medical Center

Published: April 5, 2017

CAMBRIDGE, Mass. (Apr 5, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that a new patient has been enrolled into The INSPIRE Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury) at the Carolinas Medical Center in Charlotte, NC. Domagoj Coric, M.D., of Carolina Neurosurgery and Spine Associates, Chief of Neurosurgery at the Carolinas Medical Center, and a member of the INSPIRE Study Steering Committee, performed the implantation with his partner, Byron Branch, M.D. Surgery was performed approximately 42 hours after the injury […]

View Article
InVivo Therapeutics Announces First Canadian Site for Cervical Spinal Cord Injury Study

Published: March 30, 2017

– Leading Spinal Cord Researcher Dr. Michael Fehlings and Toronto Western Hospital to be First Study Site – CAMBRIDGE, Mass. (Mar 30, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that it has received approval from the Toronto Western Hospital’s Research Ethics Board to enroll patients as part of its cervical spinal cord injury study. Toronto Western Hospital is the first study site for the company’s cervical spinal cord injury study and Michael Fehlings, M.D., Ph.D., has been named Principal Investigator at the site. Dr. Fehlings is currently Director of the Spinal Program, part of Toronto Western Hospital’s Krembil Neuroscience Centre […]

View Article
InVivo Therapeutics Appoints Christopher McNulty as Chief Financial Officer

Published: March 29, 2017

CAMBRIDGE, Mass. (Mar 29, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Christopher McNulty as Chief Financial Officer (CFO), effective March 29, 2017. He will be taking over for the interim CFO, Melanie Morel-Ferris, CPA, who will remain as the company’s Senior Director, Finance and Controller. Prior to being appointed Chief Financial Officer, Mr. McNulty served at InVivo as Senior Vice President, Business Development and Investor Relations, where he was responsible for evaluating all partnerships and licensing opportunities. In addition to his responsibilities in business development, Mr. McNulty played a key role in the company’s financings, […]

View Article
InVivo Therapeutics Announces Seventh Patient Conversion in The INSPIRE Study of the Neuro-Spinal Scaffold

Published: March 28, 2017

– Patient Converts from Complete to Incomplete Spinal Cord Injury with Sensory and Motor Improvements – CAMBRIDGE, Mass. (Mar 28, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the patient enrolled in January in the INSPIRE study of the Neuro-Spinal Scaffold has improved from a complete AIS A spinal cord injury (SCI) to an incomplete AIS B SCI in the time between the one-month and the two-month evaluations. This is the seventh out of the 11 patients (63.6% conversion rate) with at least one month of follow-up to have had an AIS grade improvement. Two additional patients are early […]

View Article
InVivo Therapeutics to Present at Needham and Company’s 16th Annual Healthcare Conference

Published: March 27, 2017

CAMBRIDGE, Mass. (Mar 27, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin, Chief Executive Officer and Chairman, will present at the Needham and Company’s 16th Annual Healthcare Conference on Wednesday, April 5, 2017 at 1:40 PM Eastern Time at the Westin NY Grand Central Hotel in New York, NY. This is the first time that the company has been invited to present at the Needham and Company Annual Healthcare Conference. During his presentation, Mr. Perrin will highlight the recent progress of the company’s Neuro-Spinal Scaffold™ program, and provide an overview of the company. A live webcast […]

View Article
InVivo to Initiate Cervical Spinal Cord Injury Study

Published: March 23, 2017

– Company Receives Investigational Testing Authorization from Health Canada to Conduct Cervical Spinal Cord Injury Study – CAMBRIDGE, Mass. (Mar 23, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Health Canada has approved the company’s Investigational Testing Authorization application to commence a clinical study of the Neuro-Spinal Scaffold™ in patients with acute, complete (AIS A) cervical (C5-T1) spinal cord injuries (SCIs). InVivo currently is in late stage conversation with several site Research Ethics Boards and expects to announce its first Canadian site in the coming weeks. “This approval is an important step towards our goal of redefining the […]

View Article
InVivo Therapeutics Announces Submission to the FDA of Its Nonclinical Studies Module for the Neuro-Spinal Scaffold

Published: March 21, 2017

– First of Three Modules to be Submitted for Product Approval – CAMBRIDGE, Mass. (Mar 21, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that it has submitted its first module containing nonclinical studies to the U.S. Food and Drug Administration (FDA) as part of its Humanitarian Device Exemption (HDE) modular submission and review process for the Neuro-Spinal Scaffold™. InVivo’s modular HDE process is based on a submission of three modules to the FDA that constitute a complete HDE submission once all have been submitted: a nonclinical studies module, a manufacturing module, and a clinical data module. This process allows […]

View Article

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on the InVivo website for historical purposes only. InVivo assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.